The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Official Title: A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Study ID: NCT00359086
Brief Summary: In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Duke University Adult Bone Marrow Transplant Clinic, Durham, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
Charles LeMoyne Hospital, Greenfield Park, Quebec, Canada
Sir Mortimer Davis-Jewish General Hospital, Montreal, Quebec, Canada
Name: Gregory Reid, MSc, MBA
Affiliation: MethylGene Inc.
Role: STUDY_DIRECTOR